腹腔镜前哨淋巴结导航手术在早期胃癌保胃治疗中的临床疗效:SENORITA试验5年结果
本研究基于SENORITA多中心随机临床试验的527例早期胃癌患者5年随访数据,比较腹腔镜标准胃切除术(LSG,n=269)与腹腔镜前哨淋巴结导航手术(LSNNS,n=258)的远期肿瘤学结局。两组5年无病生存率无显著差异(P=0.0561),5年总生存率和疾病特异性生存率亦无显著差异(P=0.7403和P=0.9586)。作者认为,考虑到LSNNS对术后生活质量的益处,LSNNS可作为早期胃癌的替代治疗选择。
要点
- SENORITA试验5年随访显示,LSG组与LSNNS组5年无病生存率无显著差异(P=0.0561)。
- LSNNS组异时性胃癌等胃癌相关事件比LSG组更频繁。
- 两组5年总生存率和疾病特异性生存率无显著差异(P=0.7403和P=0.9586)。
核心结论
- 两组5年无病生存率、疾病特异性生存率和总生存率均无显著差异。
- 作者认为,考虑到LSNNS对术后生活质量的益处,LSNNS可作为早期胃癌的替代治疗选择。
研究设计与样本
- 本研究为多中心随机临床试验SENORITA的5年随访分析,全分析集共527例早期胃癌患者,LSG组269例、LSNNS组258例。
- SENORITA试验设计旨在证明LSNNS在3年无病生存率方面非劣于LSG。
主要发现
- LSG组与LSNNS组5年无病生存率无显著差异(P=0.0561)。
- 5年随访期间,LSNNS组异时性胃癌等胃癌相关事件比LSG组更频繁。
- 两组残胃共10例复发癌经追加胃切除术治愈性切除,1例经追加内镜切除术治愈性切除。
- 基于LSNNS结果行保胃局部切除的198例患者中,2例发生远处转移。
- 两组5年总生存率和疾病特异性生存率无显著差异(P=0.7403和P=0.9586)。
关键数值与推荐
- SENORITA试验主要终点为3年无病生存率,未显示LSNNS相对LSG的非劣效性。
- 5年无病生存率比较P=0.0561,5年总生存率比较P=0.7403,5年疾病特异性生存率比较P=0.9586。
临床怎么用
- 作者认为,考虑到LSNNS对术后生活质量的益处,LSNNS可作为早期胃癌的替代治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to compare laparoscopic standard gastrectomy (LSG) and laparoscopic sentinel node navigation surgery (LSNNS) for EGC in terms of 5-year long-term oncologic outcomes. SUMMARY BACKGROUND DATA: The oncological safety of LSNNS for early gastric cancer (EGC) has not been confirmed. Three-year disease-free survival (DFS), which is the primary endpoint of the phase III multicenter randomized controlled clinical trial (SEntinel Node ORIented Tailored Approach [SENORITA] trial), did not show the non-inferiority of LSNNS relative to LSG. METHODS: The SENORITA trial, a multicenter randomized clinical trial, was designed to show that LSNNS is non-inferior to LSG in terms of 3-year DFS. In the present study, we collected 5-year follow-up data from 527 patients recruited in the SENORITA trial as the full analysis set (FAS). Disease-free survival (DFS), overall survival (OS), disease-specific survival (DSS), and recurrence patterns were evaluated using the FAS of both LSG (n=269) and LSNNS (n=258). RESULTS: The 5-year DFS was not significantly different between the LSG and LSNNS groups (P=0.0561). During the 5-year follow-up, gastric cancer-related events, such as metachronous cancer, were more frequent in the LSNNS group than in the LSG group. However, ten recurrent cancers in the remnant stomach of both groups were curatively resected by additional gastrectomy and one by additional endoscopic resection. Two of the 198 patients who underwent local resection for stomach preservation based on the LSNNS results developed distant metastasis. However, there was no statistically significant difference in the 5-year OS and DSS (P=0.7403 and P=0.9586, respectively) between the two groups. CONCLUSION: The 5-year DFS, DSS and OS did not differ significantly between the two groups. Considering the benefits of LSNNS on postoperative quality of life, LSNNS could be recommended as an alternative treatment option for EGC.
引用
- Hur H, Lee YJ, Kim YW, et al. Clinical Efficacy of Laparoscopic Sentinel Node Navigation Surgery for Stomach Preservation in Patients With Early Gastric Cancer: 5-year Results of the SENORITA Trial. Ann Surg. 2024. PMID: 38269605. doi:10.1097/SLA.0000000000006219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。